EMPAGLIFLOZIN; LINAGLIPTIN
Clinical safety rating: safe
No significant drug interactions May cause hypersensitivity reactions including anaphylaxis.
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that prolongs the activity of incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
| Metabolism | Empagliflozin is primarily metabolized via glucuronidation (UGT2B7, UGT1A3, UGT1A8, UGT1A9) with minor CYP450 involvement. Linagliptin is minimally metabolized; approximately 90% is excreted unchanged via enterohepatic system (biliary excretion) and renal elimination is negligible. |
| Excretion | Empagliflozin: ~54% renal (unchanged), ~41% fecal (primarily unchanged parent). Linagliptin: ~80% fecal (enterohepatic circulation), ~5% renal. |
| Half-life | Empagliflozin: ~12.4 h (supports once-daily dosing). Linagliptin: ~12 h (terminal half-life; long binding to DPP-4 allows once-daily dosing despite short half-life). |
| Protein binding | Empagliflozin: ~86.2% (primarily albumin). Linagliptin: 70-80% (concentration-dependent, saturable binding to DPP-4; also albumin). |
| Volume of Distribution | Empagliflozin: Vd/F ~9.6 L (0.14 L/kg; extensive tissue distribution). Linagliptin: Vd ~1000 L (14 L/kg; large due to extensive tissue binding). |
| Bioavailability | Empagliflozin: oral bioavailability ~78% (high, unaffected by food). Linagliptin: oral bioavailability ~30% (food has no effect; low due to first-pass and saturable absorption). |
| Onset of Action | Empagliflozin: onset of glycosuria within 1 h; peak effect on glucose by 2-4 weeks. Linagliptin: DPP-4 inhibition >80% at 2 h; glucose-lowering effect seen after first dose. |
| Duration of Action | Empagliflozin: 24 h (once-daily dosing). Linagliptin: >24 h (sustained DPP-4 inhibition due to saturable binding). |
10 mg empagliflozin/5 mg linagliptin orally once daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if eGFR < 30 mL/min/1.73 m². Not recommended if eGFR < 45 mL/min/1.73 m². No dose adjustment for eGFR ≥ 45 mL/min/1.73 m². |
| Liver impairment | No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh A, B, C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No dose adjustment based on age alone. Assess renal function; contraindicated if eGFR < 30 mL/min/1.73 m². Consider increased risk of volume depletion and hypotension in patients aged ≥75 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions May cause hypersensitivity reactions including anaphylaxis.
| FDA category | Animal |
| Breastfeeding | Empagliflozin: Unknown if excreted in human milk; animal studies show excretion in milk. Due to potential for adverse effects on the developing infant (e.g., renal effects), breastfeeding is not recommended. Linagliptin: Unknown if excreted in human milk; animal studies show low levels in milk. Caution is advised. Both drugs: M/P ratio not available. Manufacturer recommends discontinuing drug or breastfeeding. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | Nasopharyngitis |
| Serious Effects |
["History of serious hypersensitivity reaction to empagliflozin, linagliptin, or any excipient","Severe renal impairment (eGFR < 30 mL/min/1.73 m²), end-stage renal disease, or dialysis (empagliflozin)","Type 1 diabetes mellitus (empagliflozin; risk of ketoacidosis)"]
| Precautions | ["Risk of pancreatitis (linagliptin)","Risk of genital mycotic infections and urinary tract infections (empagliflozin)","Risk of volume depletion, hypotension, and acute kidney injury (empagliflozin)","Risk of ketoacidosis, including euglycemic ketoacidosis (empagliflozin)","Risk of hypoglycemia when used with insulin or sulfonylureas","Risk of heart failure (linagliptin; postmarketing reports)","Risk of bullous pemphigoid (DPP-4 inhibitors)","Risk of severe and disabling arthralgia (DPP-4 inhibitors)"] |
Loading safety data…
| Empagliflozin: Based on animal studies, empagliflozin may cause renal toxicity in the developing fetus, particularly during the second and third trimesters when fetal kidneys are maturing. Human data are limited; however, SGLT2 inhibitors are generally avoided in the second and third trimesters due to potential risk of acute kidney injury in neonates. Linagliptin: Animal studies have shown no evidence of teratogenicity at clinically relevant doses. Human data are insufficient; however, DPP-4 inhibitors are generally considered low risk during pregnancy. Overall, combination should be avoided unless clearly needed, particularly in the second and third trimesters. |
| Fetal Monitoring | Monitor blood glucose levels frequently. Monitor renal function (serum creatinine, eGFR) and electrolytes. Assess for signs of urinary tract infections or genital mycotic infections. In pregnancy, monitor fetal growth and amniotic fluid volume via ultrasound, as empagliflozin may affect renal function. Monitor for hypoglycemia, especially if used with insulin or sulfonylureas. |
| Fertility Effects | No human studies on fertility. In animal studies, empagliflozin and linagliptin showed no adverse effects on fertility at clinically relevant doses. However, empagliflozin may cause testicular toxicity in animals at high doses; relevance to humans is unknown. |